KAM
ALXN

Kazazian Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Kazazian Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$1.05M Hold
10,701
– – 1.42% 21
2019
Q2 		$1.4M Sell
10,701
-3,184
-23% -$410K 1.66% 22
2019
Q1 		$1.88M Sell
13,885
-5,977
-30% -$743K 2.61% 14
2018
Q4 		$1.93M Sell
19,862
-9,764
-33% -$1.15M 2.61% 12
2018
Q3 		$4.12M Buy
29,626
+3,132
+12% +$393K 3.86% 7
2018
Q2 		$3.29M Buy
26,494
+3,211
+14% +$375K 3.01% 9
2018
Q1 		$2.6M Buy
23,283
+6,000
+35% +$717K 2.72% 10
2017
Q4 		$2.07M Buy
17,283
+6,669
+63% +$812K 2.11% 13
2017
Q3 		$1.49M Buy
10,614
+3,891
+58% +$529K 1.82% 15
2017
Q2 		$818K Buy
6,723
+2,823
+72% +$329K 1.24% 21
2017
Q1 		$473K Buy
+3,900
New +$503K 0.66% 23

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Kazazian Asset Management's ALXN Position: Q3 2019 in Review

Kazazian Asset Management held its Alexion Pharmaceuticals (ALXN) position steady in Q3 2019 at 10,701 shares worth $1.05M. The position accounts for 1.42% of the portfolio, ranked #21.

Kazazian Asset Management first reported a position in ALXN in Q1 2017 and has held it in 11 quarters since. The position peaked at $4.12M in Q3 2018. 646 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

  • Kazazian Asset Management held 10,701 shares of Alexion Pharmaceuticals worth $1.05M as of Q3 2019.
  • Kazazian Asset Management left its Alexion Pharmaceuticals share count unchanged in Q3 2019.
  • Alexion Pharmaceuticals made up 1.42% of Kazazian Asset Management's portfolio in Q3 2019, its #21 holding.
  • Kazazian Asset Management first reported a position in Alexion Pharmaceuticals in Q1 2017 and has held it in 11 quarters since.
  • Kazazian Asset Management's Alexion Pharmaceuticals position peaked at $4.12M in Q3 2018.
  • 646 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Kazazian Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.